A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

June 30, 2015

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Dociparstat sodium

"The following induction regimen was administered:~* Cytarabine (100 mg/m2/day) via continuous intravenous (IV) infusion 24 hours daily for 7 days.~* Idarubicin (12 mg/m2/day) IV on Days 1, 2, and 3.~* Dociparstat (4 mg/kg) given over 5 minutes IV, immediately after the idarubicin dose on Day 1, followed by a continuous IV infusion (0.25 mg/kg/hr for 24 hours daily) for a total of 7 days."

Sponsors
All Listed Sponsors
collaborator

Translational Drug Development

OTHER

lead

Jazz Pharmaceuticals

INDUSTRY